Aims To (1) assess trends and variation in the market share of product types and potency sold in a legal cannabis retail market and (2) estimate how potency and purchase quantity influence price variation for cannabis flower.
INTRODUCTION
Many countries have begun to liberalize cannabis policies, particularly in Europe and the western hemisphere. Uruguay and eight states in the United States have legalized cannabis production and sale for non-medical purposes; other jurisdictions will probably follow. In 2016, Canada appointed a federal task force to create a framework for legislation to legalize nationally. The task force's report recommended developing strategies to encourage consumption of less potent cannabis, such as price or tax schemes based on potency to discourage purchase of high-potency products [1] . Such policies might once have seemed unnecessary; advocates of legalization have long argued that prohibition drives up potency, and thus legal markets would naturally deliver safer, less-potent products (e.g. [2] ). The question is more than academic, however, amid growing concerns about the health consequences of high-potency cannabis products and the demand for them [3] [4] [5] [6] .
Discussions regarding 'potency' typically concern the concentrations of delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD). Their health benefits and risks have been examined in recent reviews [7] [8] [9] [10] [11] [12] , and an emerging literature suggests that consumption of high-THC cannabis flowers is associated with greater severity of dependence [13] and adverse psychological outcomes [5, 14] . The proliferation of new high-THC products (e.g. 'shatter') and methods of consumption (e.g. 'dabbing'), particularly in jurisdictions allowing recreational and/or medical cannabis sales [15, 16] , has raised additional questions, as their use and consequences have only recently begun to be examined [17] [18] [19] [20] [21] , and it is difficult to predict how legalization will influence their demand [22, 23] . Further, there is no consensus about whether individuals who use products with higher concentrations of THC titrate their doses [24, 25] .
There are also questions about the relationship between potency and price. Users report being willing to pay more for higher potency cannabis [26, 27] and there is a positive association between price and potency [28] , but consumers in illegal markets for cannabis have only limited information about potency and quality. For instance, Ben Lakhdar [28] showed that although French consumers' perceptions of cannabis potency were associated positively with actual potency as assayed in the laboratory, there remained large gaps between perceived and actual potency. How all this pertains to cannabis sold in legal markets is unknown, as characteristics of quality beyond potency, including contaminants, consistency and freshness, are probably less variable in regulated legal markets than their illicit counterparts.
Events in the United States allow an empirical investigation of potency and prices in legal cannabis markets, as the states that allow cannabis sales for nonmedical use neither discourage the consumption of highpotency products nor impose potency limits (except for edibles). This study examines the universe of cannabis purchases in Washington State's pioneering legal retail market.
In 2012, voters in Washington passed Initiative 502, which legalized cannabis possession and use for non-medical purposes, and established a framework for state-licensed production, distribution and sales to be regulated by the Liquor and Cannabis Board (LCB). A traceability system was established to track inventory from seed-to-sale, and the first licensed retailer opened in July 2014. Transactions throughout market levels (i.e. from producers to processors to retailers) were each taxed at 25%, and additional state (6%) and local sales taxes applied at the point of purchase [29] . Effective from July 2015, the tax scheme was changed to a single 37% excise tax at retail, in addition to state and local sales taxes as before. The medical cannabis industry, which had been operational since 1998, was folded into the recreational market effective from 1 July 2016 [30, 31] . As of 12 December 2016, LCB had issued 467 licenses for retailers, 141 for processors, 917 for producer-processors and 174 for producers [32] .
To improve understanding of how cannabis legalization shapes product variety, potency and prices, we used data from Washington's traceability system to analyze more than 30 million cannabis purchases made between 7 July 2014 and 30 September 2016. The study aims were to: (1) assess trends and variation in the types and potency of cannabis products sold and (2) estimate how potency, quantity discounts and other factors influence cannabis flower prices in this market.
METHODS

Design
Retail sales data were obtained through Washington's cannabis traceability system, linked to additional productand licensee-related information. After excluding observations with missing or non-positive price values (0.2%), the data set included 44 482 176 rows, each identifying one line in the sales logs of 36 001 228 separate retail transactions that occurred between the first day of retail sales (7 July 2014) and 30 September 2016. Each observation is akin to a single line on a cash register receipt, referred to hereafter as an 'item' for brevity, although sometimes a few identical items appear on a single line, indicating that a customer is buying multiple units of that item. Hence, these data are finer-grained than transaction-level data; one purchase (i.e. one payment event by the customer) can involve multiple items and thus generate multiple rows in this data set. For each observation, the data set provides reported date of sale, item weight, THC and CBD content, retail price, product category, retail store address and an identification number for the producer or processor responsible for creating the final product. Currently, the data set does not provide information to distinguish sales made from stores with medical endorsements, or of partially tax-exempt marijuana products.
For our first aim, descriptive statistics and linear regressions were used to estimate variation and trends in product types and potency. Analyses of potency were restricted to two types of products: flowers and extracts for inhalation. 'Flowers' refer to the traditional form of dried herbal cannabis. 'Extracts for inhalation' include products either consisting of cannabis resin ('kief ' or 'hash') or manufactured from extracted cannabinoids, including vaporizer cartridges and solid concentrate ('wax' or 'shatter'). We focused on these product types because they comprise the vast majority of sales and, unlike with edibles, their potency characteristics are readily retrievable from the traceability data.
For our second aim, hedonic price regressions were used to determine how cannabis flower prices vary with product and market characteristics. This technique [33] has been employed in the valuation of agricultural products, beverages, real estate and automobiles, among other items. The basic concept is that firms offer differentiated products to satisfy heterogeneous preferences of consumers. Each set of product attributes commands a different price based on consumers' willingness to pay and the marginal cost of producing each characteristic. Price analysis was restricted to cannabis flower products, as flower represents the largest share of the market, is a more homogeneous product category that can be well-characterized by measuring its weight and potency, and has been examined in previous literature.
Measures
Expenditures were measured in US dollars, inclusive of excise taxes but not state or local sales taxes. Trends in product variety were measured using monthly share of expenditures by product type or potency category.
The traceability system reports potency as measured via laboratory testing. THC concentration was calculated as the estimated total weight of THC after decarboxylation as a percentage of total item weight (see Supporting information Appendix for details). Similarly, CBD concentration was measured as total weight of CBD as a percentage of item weight.
It is worth noting that the integrity of Washington's accredited cannabis-testing laboratories has been challenged. There are anomalies in the data, incentives to produce results favorable to customers and limited enforcement mechanisms. However, criticism has focused largely upon testing for contaminants, not potency [34] , and on edible products (which we exclude), for which testing is technically more difficult [35] . Further, in April 2016, LCB increased enforcement by issuing new rules for a proficiency testing program to hold laboratories accountable (effective from August 2016) [36] , and in May issued its first laboratory certification suspension [37] . Sensitivity analyses motivated by these concerns are provided in the see Supporting information Appendix.
For the cannabis flower price analysis, the outcome measure is the item-level excise tax-inclusive price per gram, calculated as the excise tax-inclusive price divided by the quantity purchased in grams and log-transformed. Key predictors are item weight (measured in grams and log-transformed), as well as the measures of THC and CBD concentration described above.
Additional covariates in the hedonic price regressions were constructed from the reported date of sale. These included separate indicator variables for whether a sale occurred (a) within the first 3 months of a store's operation to account for store opening discounts, (b) on 20 April, widely recognized as a cannabis holiday, (c) during the week prior to the cannabis holiday (14-19 April) and (d) after 30 June 2015 to account for the change in Washington's cannabis excise tax. All regressions also controlled for time effects through indicator variables for month, day of month, and day of week, as well as a 5th-order polynomial time trend.
Data analysis
To address our first aim, trends in product variety and flower potency were assessed by calculating the monthly proportion of total excise tax-inclusive market expenditures by product type or (among flower products) by THC category. We selected October 2014 as the baseline month for calculating market growth over time (to September 2016) to allow some degree of market stabilization after the first store opened in July of that year. We estimated whether there was a statistically significant linear association between market share and time using a regression model with year-month (e.g. October 2014, September 2014) treated as a continuous variable. To compare levels and variation of THC and CBD across cannabis flower and extracts, we examined histograms and descriptive statistics and calculated means and coefficients of variation (CV), defined as the standard deviation divided by the mean.
To address our second aim, graphical evidence was presented to illustrate price variation for cannabis flower over time and across purchase quantities. Multivariate linear regression models were estimated at the item level to relate flower prices to potency and quantity, controlling for other store-level, producer-level and time-level covariates. Observations with outlying price and quantity measures were trimmed to reduce skew in the data, thus our analysis may be conservative with respect to the extent of price dispersion. Table 1 provides descriptive statistics for our sample characteristics and the variables used in the regression analysis.
The regression models included the natural log of excise tax-inclusive price per gram as the outcome, and log-transformed purchase weight, total THC concentration and CBD concentration as key predictors. To account for potential time-invariant retail store or producer heterogeneity, we estimated additional specifications controlling for retail store fixed effects alone, producer fixed effects alone and both retail store and producer fixed effects. Details of variables, sample specification, modeling strategy and sensitivity analyses for our primary results are provided in the see Supporting information Appendix.
For all price regressions, robust standard errors were clustered at the dispensary location level using the sandwich estimator to allow for non-independence of observations within a retail store [38] . The data set was prepared using R version 3.3.1 software [39] and Stata/MP version 14.1 software [40] was used to implement all statistical analyses.
RESULTS
Product variety and potency
Washington's retail cannabis market has expanded rapidly ( Fig. 1) , with excise tax-inclusive sales in September 2016 reaching $98 million. The composition of products has also changed. While cannabis flower still accounts for twothirds of expenditures, its market share has declined by 22.4% (linear trend P < 0.001) relative to October 2014 (see Supporting information, Table S2 ). Cannabis extracts for inhalation now comprise more than 21% of expenditures, an increase of 145.8% (P < 0.001) relative to October 2014. Market share for other cannabis products (e.g. edibles, tinctures and suppositories) also increased between October 2014 and September 2016, although this trend was not significant (P = 0.058), and these products still account for only 12.1% of expenditures. Figure 2a plots the distributions of THC composition for flowers and extracts separately using all years of available data. Compared to estimates from illicit cannabis markets [41] [42] [43] , THC potency is strikingly high for flower (mean 20.6%) and extracts for inhalation (mean 68.7%). Potency is more variable for extracts, but only proportionally; the CV of THC content for both product forms is just over 0.2.
High-CBD forms of cannabis have attracted attention for their reputed medical properties [44] , but they account for a tiny share of Washington's legal retail market. The distribution of CBD composition is highly skewed (Fig. 2b) ; average CBD for flower products is 0.34% and for extracts is 1.8%. Even after July 2016 (when sales of medical cannabis were restricted to Exclusion of quantity and price outliers is explained in the text, with further detail in the Supporting information, Appendix. THC = delta-9-tetrahydrocannabinol; CBD = cannabidiol.
licensed retailers included in this data set), items with greater than 4% CBD and less than 1% THC accounted for just 0.14% of sales revenue in the markets for flower and extracts for inhalation.
Among flower products, the market share of strains with greater than 15% THC has grown to 92.5% of flower sales (Fig. 3) , and (not shown) an even greater share of THC consumption. Flowers with less than 10% THC now account for less than 2% of flower expenditures, and market share for flower products with 10-15% THC has declined significantly by 60.4% since October 2014 (linear trend P = 0.007; see Supporting information, Table S2 ). In contrast, the market share of flower products with more than 20% THC has increased by 48.4% since October 2014, now accounting for 56.5% of retail expenditures on cannabis flower; however, this linear trend was not significant (P = 0.228).
Price variation in the market for cannabis flower
Prices for flower in Washington have fallen sharply since the market opened (Fig. 4) , but there is substantial variation in prices around that trend that does not appear to be merely an artifact of the market's nascence. Indeed, since March 2015 the CV has remained relatively stable at approximately 0.3.
Some variation stems from quantity discounts, which have been studied in markets for illicit drugs [45] [46] [47] . Figure 5a presents box-and-whisker plots for the taxinclusive price per gram separately by purchase size category. The corresponding plot for price per milligram of THC (Fig. 5b) is similar, as there is little variation in potency across item sizes. The plots suggest the existence of quantity discounts for purchases greater than 5 g in weight, with larger discounts for purchases of approximately an ounce. Nevertheless, smaller transaction quantities dominate the market. Purchase sizes less than 5 g in weight accounted for nearly 75% of all cannabis flower expenditures in 2016.
To characterize more precisely the determinants of price variation, Table 2 presents results from the hedonic price regressions. The coefficient on ln(quantity) can be interpreted as the size-elasticity of the per-gram price, which is a function of the product mark-up and the conversion factor that transforms some larger quantity to a smaller one [45] . Based on specification (iv), which includes both retail store and producer fixed effects, the estimated discount elasticity indicates that a 10% increase in the size of a transaction is associated with a 0.62% reduction in the unit price. In other words, consumers purchasing an eighth of an ounce (3.55 g) of flower on average pay approximately 16% less on a per gram basis than do consumers purchasing 1 g at a time.
All specifications show a statistically significant, but small, relationship between tax-inclusive price per gram and potency. Depending on the particular regression model and accounting for the 95% confidence intervals (CI), a one percentage point increase in THC (CBD) potency is associated with a 1-2% (1.5-2.5%) increase in price. As THC potency averages approximately 20%, a roughly 5% increase in THC is associated with increases in price of less than 2%. Thus, the cost per unit of THC is lower for the more potent forms.
Prices are discounted significantly [coefficient = À0.30; confidence interval (CI) = À0.35 to À0.27] on 20 April, and there is evidence of smaller but significant price reductions in the week leading up to 20 April (coefficient = À0.02; CI = À0.03 to À0.01). In model (iv), that accounts for both producer and retailer heterogeneity, the included variables explain approximately 54% of the observed variation in tax-inclusive price per gram of cannabis flower.
DISCUSSION
Washington's legal cannabis market has trended towards higher-THC products, as flower products with THC concentration more than 20% and extract products with more than 60% THC are now commonplace. By comparison, national estimates of average THC level for cannabis seized during prohibition did not exceed 5% in the United States until 2001 [48] , and as recently as 2010 typically from ranged 8 to 13% [41, 42] . Potency in Washington State also generally exceeds the 15% limit for cannabis products that has been discussed in the Netherlands [49] . In 2015, the strongest Nederwiet sold in Dutch coffeeshops averaged 17% THC (± 3.4% [43] ). This directly contradicts Cowan's [50] so-called 'Iron Law of Prohibition', which asserts that tougher enforcement drives up potency, and legalization would necessarily lead to less-potent drugs. As observed previously [51] , the actual experience with cannabis liberalization's effect on potency has proved to be very different than that predicted by analysis of alcohol prohibition and drug markets under prohibition [52, 53] .
The growing popularity of extract products in Washington's retail market is consistent with other research using data from social media [15, 16] , and may reflect both supply-side and demand-side factors. Lower enforcement risks for suppliers have increased innovation of more advanced methods of extraction, as well as provided greater access to the raw inputs needed to produce concentrates [54] . Demand for alternatives to smoked cannabis may also be a factor, as exploratory studies have indicated a growing perception that vaporizing is a healthier and more efficient method of consumption than is smoking [55] [56] [57] , analogous to perceptions that electronic nicotine delivery systems are less harmful than cigarettes [58] . However, there is concern about the increased consumption of extracts, as their potential health consequences are largely unknown [59] . 
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*P < 0.05; **P < 0.01; ***P < 0.001. All specifications include month, day of month, and day of week fixed effects and a 5th order polynomial time trend. Column (ii) adds retail store fixed effects, column (iii) replaces retail store fixed effects with producer fixed effects and column (iv) includes both retail store and producer fixed effects. Robust standard errors are clustered at the retail store level, and 95% confidence intervals are provided in parentheses. THC = delta-9-tetrahydrocannabinol; CBD = cannabidiol.
Prices fell sharply after the opening of legal retail stores as new retailers entered the market and production expanded. The coefficient of variation for prices has stabilized at approximsately 0.3. This suggests much less price variability than what Reuter & Caulkins [60] observed for US cocaine and heroin markets, and much greater variability than that found for most conventional goods [61] or groceries [62] . It is also greater than the price variability observed in California for beer (0.19) or spirits (0.24), but slightly lower than for wine (0.34) [63] .
Our estimated quantity discount elasticity of À0.06 is much smaller than estimates for the illicit market in the United States, which ranged between À0.15 and À0.57 [45, 64] , or Australia, which ranged between À0.2 and À0.3 [46, 65] . There are a number of potential explanations. For one, potency has largely been excluded from prior models due to data limitations. If in those data sets smaller purchases had higher average potency (e.g. because low potency commercial-grade material was sold by the ounce, not by the gram), then omitted variable bias would lead past estimates to overstate quantity discounts. While our data do not suggest that there is a tendency for larger items to have lower THC content (Supporting information, Fig. S1 ), illicit markets may differ in this regard. Additionally, our analysis pertained only to retail purchases, which Washington's law restricts to no more than 1 ounce; future analyses of wholesale transactions within the traceability data may show larger quantity discounts between wholesale and retail quantities.
Another explanation recognizes that quantity discounts are the flip-side of price mark-ups, which in a competitive market generally reflect the costs of distributing drugs. If legalization lowers the risks and other costs of distributing cannabis, then that would naturally produce lower mark-ups and, hence, smaller quantity discounts. Overall, our findings do not indicate that retailers are offering significant incentives for consumers to make larger purchases.
Our findings are consistent with product innovation, product development and marketing investments characteristic of the profit-oriented marijuana industry established by Washington's legal framework [66] . The consequences of smaller price mark-ups and higher potency remain to be seen. Washington is allowing the potency and price of legal cannabis to be shaped by the market; remember, this is a choice [67] . Potential policy levers for controlling potency include potency-driven taxes, price floors linked to potency, or THC limits. Although these may be challenging to enforce and no evidence yet exists on what threshold constitutes a 'safe' potency, risk-averse jurisdictions considering or implementing non-medical legalization may nonetheless want to discourage consumption of high-potency products until more is learned about their health effects.
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